Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

Summary

This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.

The briefing includes analysis of KOL opinion on the following topic areas-

- Efficacy & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients)

- Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients)

- Views on dose response for upadacitinib

Key Highlights

- Majority of KOLs had a positive opinion of upadacitinib's efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial

- Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial

- KOLs appeared unsure of upadacitinib's comparative efficacy vs. other JAK inhibitors, with many citing the need for head-to-head studies.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

- Interviews performed in Q2 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Upadacitinib, rheumatoid arthritis, adalimumab, baricitinib, JAK inhibitors, SELECT-COMPARE, tofacitinib


Companies

AbbVie

Pfizer

Lilly

Gilead

Galapagos